#1 Clinical Trials Search in Europe

AUTOLOGOUS DENDRITIC CELLS PULSED WITH ALLOGENEIC TUMOUR CELL LYSATE

Clinical trials are studying AUTOLOGOUS DENDRITIC CELLS PULSED WITH ALLOGENEIC TUMOUR CELL LYSATE in people with lung cancer. These studies look at whether the treatment can help keep the cancer from growing after first treatment, and they measure outcomes such as safety and progression-free survival.

Table of contents

Trial overview

The available trial data describe one interventional study, which means the researchers gave a planned treatment and then measured the results.[1] The study investigated AUTOLOGOUS DENDRITIC CELLS PULSED WITH ALLOGENEIC TUMOUR CELL LYSATE in people with lung cancer, with a focus on extensive stage small cell lung cancer.[1]

Who was studied

The trial enrolled people with extensive stage small cell lung cancer, a fast-growing type of lung cancer that has spread widely.[1] These participants had already received induction treatment, meaning first treatment given before the study treatment was started.[1]

Treatment and study setting

The study tested AUTOLOGOUS DENDRITIC CELLS PULSED WITH ALLOGENEIC TUMOUR CELL LYSATE together with atezolizumab as maintenance treatment after induction therapy.[1] The trial record lists intradermal injection for the dendritic cell treatment and intravenous infusion for atezolizumab, which means the medicines were given through the skin and through a vein.[1]

This was a maintenance study, so the goal was not first-line treatment of the cancer, but treatment given after the first treatment phase to help keep the disease under control.[1]

Trial phase and status

The study was a Phase 2/3 trial.[1] Phase 2/3 studies are later-stage trials that look more closely at whether a treatment works and help confirm the findings in a larger setting.[1] The trial status was Completed, and the enrollment was 20 participants.[1]

Main endpoint

The main outcome was progression-free survival (PFS) rate at 6 months.[1] This means the researchers checked how many participants were alive and had no disease progression, or cancer growth, at 6 months, using the RECIST v1.1 method to assess the cancer.[1]

What the results mean for patients

For patients, this trial was designed to see whether AUTOLOGOUS DENDRITIC CELLS PULSED WITH ALLOGENEIC TUMOUR CELL LYSATE could help extend the time before the cancer got worse after initial treatment.[1] The study did not include many people, so it is best seen as an early step in learning how this treatment may perform in this cancer setting.[1]

Trial ID Phase Condition studied Status Enrollment
NCT04487756 Phase 2/3 Extensive stage small cell lung cancer Completed 20

FAQ

  • What are clinical trials of AUTOLOGOUS DENDRITIC CELLS PULSED WITH ALLOGENEIC TUMOUR CELL LYSATE trying to find out? The trial data focus on whether this treatment can help as maintenance therapy after first treatment. The main goal is to see if people stay alive and without cancer growth for longer.
  • Who was studied in the trial data? The study enrolled people with extensive stage small cell lung cancer, which is a fast-growing type of lung cancer. These patients had already received induction treatment before joining the maintenance study.
  • What phase was the trial? The trial was a Phase 2/3 study. This means it was designed to gather more evidence about how well the treatment works and to support later-stage testing.
  • What treatment was tested with AUTOLOGOUS DENDRITIC CELLS PULSED WITH ALLOGENEIC TUMOUR CELL LYSATE? The trial tested a combination with atezolizumab, given as maintenance treatment. The study used intradermal injection for the dendritic cell treatment and intravenous infusion for atezolizumab.
  • What result was measured in the trial? The main result was progression-free survival rate at 6 months. This means the study checked how many participants were alive and had not shown cancer progression after 6 months.

Ongoing Clinical Trials on AUTOLOGOUS DENDRITIC CELLS PULSED WITH ALLOGENEIC TUMOUR CELL LYSATE

  • Study of Atezolizumab and Dendritic Cell Vaccine for Maintenance Treatment in Patients with Extensive Stage Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Spain

Glossary

  • Extensive stage small cell lung cancer: A fast-growing lung cancer that has spread widely in the body.
  • Maintenance treatment: Treatment given after the first main treatment to help keep the cancer under control.
  • Induction treatment: The first treatment given to reduce the cancer before the next treatment step.
  • Phase 2/3: A later-stage clinical trial that looks more closely at how well a treatment works and helps confirm results.
  • Interventional study: A study in which participants receive a planned treatment so researchers can measure its effects.
  • Progression-free survival: The length of time during and after treatment when the cancer does not get worse.
  • RECIST v1.1: A standard way doctors and researchers measure whether a tumor has grown, shrunk, or stayed the same.
  • Intradermal injection: An injection placed into the skin.
  • Intravenous infusion: A treatment given through a vein, usually slowly over time.

References